ET
ARQT icon

Entropy Technologies’s Arcutis Biotherapeutics ARQT Stock Holding History

Entropy Technologies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$584K Buy
22,285
+4,321
+24% +$101K 0.02% 632
2026
Q1 		$423K Buy
17,964
+5,820
+48% +$149K 0.02% 621
2025
Q4 		$353K Buy
12,144
+792
+7% +$20.3K 0.02% 662
2025
Q3 		$214K Buy
+11,352
New +$179K 0.02% 739
2025
Q2 		– Sell
-15,744
Closed -$246K – 778
2025
Q1 		$246K Buy
+15,744
New +$222K 0.02% 586
2024
Q3 		– Sell
-11,772
Closed -$109K – 720
2024
Q2 		$109K Buy
+11,772
New +$106K 0.01% 630

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Entropy Technologies's ARQT Position: Q2 2026 in Review

Entropy Technologies increased its Arcutis Biotherapeutics (ARQT) stake by 24% in Q2 2026, buying an estimated $101K and bringing the position to 22,285 shares worth $584K. The position accounts for 0.02% of the portfolio, ranked #632.

Entropy Technologies first reported a position in ARQT in Q2 2024 and has held it in 6 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Entropy Technologies held 22,285 shares of Arcutis Biotherapeutics worth $584K as of Q2 2026.
  • Entropy Technologies bought 4,321 Arcutis Biotherapeutics shares in Q2 2026, an estimated $101K.
  • Arcutis Biotherapeutics made up 0.02% of Entropy Technologies's portfolio in Q2 2026, its #632 holding.
  • Entropy Technologies first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 6 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.